Novel role for epalrestat: protecting against NLRP3 inflammasome-driven NASH by targeting aldose reductase

Abstract Background Nonalcoholic steatohepatitis (NASH) is a progressive and inflammatory subtype of nonalcoholic fatty liver disease (NAFLD) characterized by hepatocellular injury, inflammation, and fibrosis in various stages. More than 20% of patients with NASH will progress to cirrhosis. Currentl...

Full description

Bibliographic Details
Published in:Journal of Translational Medicine
Main Authors: Wei Shi, Guang Xu, Yuan Gao, Jun Zhao, Tingting Liu, Jia Zhao, Huijie Yang, Ziying Wei, Hui Li, An-Long Xu, Zhaofang Bai, Xiaohe Xiao
Format: Article
Language:English
Published: BMC 2023-10-01
Subjects:
Epalrestat
NASH
Aldose reductase
NLRP3 inflammasome
NLRP3 inflammasome-driven disease
Online Access:https://doi.org/10.1186/s12967-023-04380-4

Internet

https://doi.org/10.1186/s12967-023-04380-4

Similar Items